Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsTransplantation ChimeraStem CellsSurvival RateTreatment OutcomeBone Marrow TransplantationGraft vs Leukemia EffectTissue DonorsMyeloablative AgonistsBusulfanGraft SurvivalRemission InductionRecurrenceVidarabineDisease-Free SurvivalGraft vs Tumor EffectSurvival AnalysisRetrospective StudiesHistocompatibility TestingLymphocyte TransfusionImmunosuppressive AgentsCombined Modality TherapyLeukemia, Myeloid, AcuteMultiple MyelomaLeukemiaSiblingsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCord Blood Stem Cell TransplantationCytomegalovirus InfectionsSalvage TherapyHematopoietic Stem CellsLiver TransplantationTime FactorsMinor Histocompatibility AntigensWhole-Body IrradiationLymphocyte DepletionMyelodysplastic SyndromesAntilymphocyte SerumCell SurvivalNeoplasm, ResidualVirus ActivationPrecursor Cell Lymphoblastic Leukemia-LymphomaHistocompatibilityFollow-Up StudiesAntineoplastic Combined Chemotherapy ProtocolsMelphalanChimerismCyclophosphamidePrognosisHepatic Veno-Occlusive DiseaseMesenchymal Stem Cell TransplantationMortalityCytomegalovirusT-LymphocytesAcute DiseaseHematopoietic Stem Cell MobilizationKidney TransplantationPrimary MyelofibrosisCell TransplantationAnemia, AplasticHLA AntigensHematologic DiseasesEmbryonic Stem CellsAntineoplastic AgentsLeukemia, Myeloid, Accelerated PhaseAntigens, CD34CytarabineImmunosuppressionAntibodies, NeoplasmBenzamidesTransplantation ImmunologyProspective StudiesRoseolovirus InfectionsLeukemia, MyeloidAdult Stem CellsImmunocompromised HostLymphoproliferative DisordersGraft RejectionHodgkin DiseaseFusion Proteins, bcr-ablPyrimidinesReceptors, Purinergic P2X5Risk FactorsLymphoma, Non-HodgkinInfectionNuclear FamilyHeart TransplantationPiperazinesKaplan-Meier EstimateGranulocyte Colony-Stimulating FactorGanciclovirCyclosporineCohort Studies